These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

401 related items for PubMed ID: 23976960

  • 1. Clinical trial to evaluate the safety and immunogenicity of a trivalent surface antigen seasonal influenza vaccine produced in mammalian cell culture and administered to young and elderly adults with and without A(H1N1) pre-vaccination.
    Loebermann M, Voss U, Meyer S, Bosse D, Fritzsche C, Klammt S, Frimmel S, Riebold D, Reisinger EC.
    PLoS One; 2013; 8(8):e70866. PubMed ID: 23976960
    [Abstract] [Full Text] [Related]

  • 2. Immunogenicity and safety of an inactivated 2012/2013 trivalent influenza vaccine produced in mammalian cell culture (Optaflu®): an open label, uncontrolled study.
    Vinnemeier CD, Fischer-Herr J, Meyer S, Liebig K, Theeß W, Burchard GD, Cramer JP.
    Hum Vaccin Immunother; 2014; 10(2):441-8. PubMed ID: 24240428
    [Abstract] [Full Text] [Related]

  • 3. A 2013/2014 northern hemisphere season surface antigen inactivated trivalent influenza vaccine--Assessing the immunogenicity and safety in an open label, uncontrolled study.
    Roggelin L, Vinnemeier CD, Meyer S, Witte K, Marx L, Theeß W, Burchard GD, Rolling T, Cramer JP.
    Hum Vaccin Immunother; 2015; 11(10):2370-5. PubMed ID: 26114800
    [Abstract] [Full Text] [Related]

  • 4. A phase III, open-label, single-arm, study to evaluate the safety and immunogenicity of a trivalent, surface antigen inactivated subunit influenza virus vaccine produced in mammalian cell culture (Optaflu®) in healthy adults.
    Loebermann M, Fritzsche C, Geerdes-Fenge H, Heijnen E, Kirby D, Reisinger EC.
    Infection; 2019 Feb; 47(1):105-109. PubMed ID: 30298473
    [Abstract] [Full Text] [Related]

  • 5. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB, Neuzil KM, Zhu Y, Fairchok MP, Gagliano ME, Monto AS, Englund JA.
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [Abstract] [Full Text] [Related]

  • 6. Safety, immunogenicity and cross-reactivity of a Northern hemisphere 2013-2014 seasonal trivalent inactivated split influenza virus vaccine, Anflu®.
    Shen Y, Hu Y, Meng F, Du W, Li W, Song Y, Ji X, Huo L, Fu Z, Yin W.
    Hum Vaccin Immunother; 2016 May 03; 12(5):1229-34. PubMed ID: 26934750
    [Abstract] [Full Text] [Related]

  • 7. Safety and immunogenicity of a seasonal trivalent inactivated split influenza vaccine: a phase I randomized clinical trial in healthy Serbian adults.
    Stevanovic G, Lavadinovic L, Filipovic Vignjevic S, Holt R, Ilic K, Berlanda Scorza F, Sparrow E, Stoiljkovic V, Torelli G, Madenwald T, Socquet M, Barac A, Ilieva-Borisova Y, Pelemis M, Flores J.
    Hum Vaccin Immunother; 2018 Mar 04; 14(3):579-586. PubMed ID: 29239682
    [Abstract] [Full Text] [Related]

  • 8. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years.
    Kieninger D, Sheldon E, Lin WY, Yu CJ, Bayas JM, Gabor JJ, Esen M, Fernandez Roure JL, Narejos Perez S, Alvarez Sanchez C, Feng Y, Claeys C, Peeters M, Innis BL, Jain V.
    BMC Infect Dis; 2013 Jul 24; 13():343. PubMed ID: 23883186
    [Abstract] [Full Text] [Related]

  • 9. Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age.
    Gorse GJ, Falsey AR, Fling JA, Poling TL, Strout CB, Tsang PH.
    Vaccine; 2013 May 01; 31(19):2358-65. PubMed ID: 23499604
    [Abstract] [Full Text] [Related]

  • 10. Immunogenicity and safety of a novel seasonal influenza preservative-free vaccine manufactured in Kazakhstan: Results of a randomized, comparative, phase II clinical trial in adults.
    Sarsenbayeva G, Volgin Y, Kassenov M, Issagulov T, Bogdanov N, Sansyzbay A, Stukova M, Buzitskaya Z, Кulmagambetov I, Davlyatshin T, Khairullin B.
    Hum Vaccin Immunother; 2018 Mar 04; 14(3):609-614. PubMed ID: 29112488
    [Abstract] [Full Text] [Related]

  • 11. Comparison of the immunogenicity and safety of the conventional subunit, MF59-adjuvanted, and intradermal influenza vaccines in the elderly.
    Seo YB, Choi WS, Lee J, Song JY, Cheong HJ, Kim WJ.
    Clin Vaccine Immunol; 2014 Jul 04; 21(7):989-96. PubMed ID: 24828092
    [Abstract] [Full Text] [Related]

  • 12. Quadrivalent Influenza Vaccine-Induced Antibody Response and Influencing Determinants in Patients ≥ 55 Years of Age in the 2018/2019 Season.
    Ganczak M, Dubiel P, Drozd-Dąbrowska M, Hallmann-Szelińska E, Szymański K, Brydak LB.
    Int J Environ Res Public Health; 2019 Nov 14; 16(22):. PubMed ID: 31739554
    [Abstract] [Full Text] [Related]

  • 13. Influenza Vaccine-Induced Antibody Responses Are Not Impaired by Frailty in the Community-Dwelling Elderly With Natural Influenza Exposure.
    Narang V, Lu Y, Tan C, Camous XFN, Nyunt SZ, Carre C, Mok EWH, Wong G, Maurer-Stroh S, Abel B, Burdin N, Poidinger M, Tambyah PA, Bosco N, Visan L, Ng TP, Larbi A.
    Front Immunol; 2018 Nov 14; 9():2465. PubMed ID: 30405641
    [Abstract] [Full Text] [Related]

  • 14. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA, Walter EB, Gbadebo A, Monto AS, Zhu Y, Neuzil KM.
    Pediatrics; 2006 Sep 14; 118(3):e579-85. PubMed ID: 16950949
    [Abstract] [Full Text] [Related]

  • 15. Serological response to influenza A H1N1 vaccine (Pandemrix®) and seasonal influenza vaccine 2009/2010 in renal transplant recipients and in hemodialysis patients.
    Ott U, Sauerbrei A, Lange J, Schäfler A, Walther M, Wolf G, Wutzler P, Zell R, Krumbholz A.
    Med Microbiol Immunol; 2012 Aug 14; 201(3):297-302. PubMed ID: 22350187
    [Abstract] [Full Text] [Related]

  • 16. Immunological persistence of a seasonal influenza vaccine in people more than 3 years old.
    Bai Y, Shi N, Lu Q, Yang L, Wang Z, Li L, Han H, Zheng D, Luo F, Zhang Z, Ai X.
    Hum Vaccin Immunother; 2015 Aug 14; 11(7):1648-53. PubMed ID: 26083828
    [Abstract] [Full Text] [Related]

  • 17. The safety and immunogenicity of trivalent inactivated influenza vaccination: a study of maternal-cord blood pairs in Taiwan.
    Lin SY, Wu ET, Lin CH, Shyu MK, Lee CN.
    PLoS One; 2013 Aug 14; 8(6):e62983. PubMed ID: 23762229
    [Abstract] [Full Text] [Related]

  • 18. Safety and immunogenicity of a trivalent single dose seasonal influenza vaccine containing pandemic A(H1N1) antigen in younger and elderly subjects: a phase III open-label single-arm study.
    Loebermann M, Anders G, Brestrich G, Fritzsche C, Klammt S, Boršo D, Frimmel S, Riebold D, Reisinger EC.
    Vaccine; 2011 Feb 01; 29(6):1228-34. PubMed ID: 21167116
    [Abstract] [Full Text] [Related]

  • 19. Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age.
    Vesikari T, Block SL, Guerra F, Lattanzi M, Holmes S, Izu A, Gaitatzis N, Hilbert AK, Groth N.
    Pediatr Infect Dis J; 2012 May 01; 31(5):494-500. PubMed ID: 22301476
    [Abstract] [Full Text] [Related]

  • 20. Immunogenicity and Safety of Trivalent Split Influenza Vaccine in Healthy Korean Adults with Low Pre-Existing Antibody Levels: An Open Phase I Trial.
    Kang K, Han S, Hong T, Jeon S, Paek J, Kang JH, Yim DS.
    Yonsei Med J; 2016 Nov 01; 57(6):1354-60. PubMed ID: 27593862
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.